Articles
27. 10. 2015 Cancer in the older population of the Czech Republic
Population ageing has become a challenge to cancer care in developed countries. Particularities of the older population must be taken into account when considering cancer treatment. However, there is a lack of consensus on guidelines for this population due to the underrepresentation of older patients in clinical trials.
15. 1. 2014 Personalised invitations of Czech citizens to cancer screening programmes
In January 2014, a project of personalised invitations for cancer screening programmes was launched in the Czech Republic. In particular, citizens are invited to participate in colorectal cancer screening (men and women), as well as breast cancer screening and cervical cancer screening (women). Personalised invitations are aimed at citizens who have not participated in cancer screening programmes in the long term, and therefore are at a higher risk of developing cancer. The project is expected to increase participation rates in Czech cancer screening programmes.
» Archive
Registries monitoring the use of targeted therapies
Clinical registries present an important tool recording the administration of biological therapies in the Czech Republic and its results. The Czech Society for Oncology maintains clinical registries of cancer patients treated with biological therapies in Comprehensive Cancer Centres. These registries make it possible to evaluate the benefits and safety of treatment. Although recording data on biological therapies is not obligatory, data on more than 90 % of patients treated with these preparations are recorded. Data is recorded in a de-identified form, i.e. a specific patient cannot be identified. Registries on the administration of biological therapies are maintained by the Czech Society of Oncology in cooperation with the Institute of Biostatistics and Analyses Ltd, and the Masaryk Memorial Cancer Institute. More information is available in the description of the below-mentioned projects.
CAR-TOOL
The aim of the project is to collect and evaluate data from real clinical practice, which are related to the administration of CAR-T cell therapy in patients with certain hematological malignancies who face poor prognosis. CAR-T cell therapy is currently indicated in adult patients with certain types of non-Hodgkin's lymphoma, incl. aggressive, relapsing or refractory diffuse large B-cell lymphoma, primary mediastinal B-lymphoma, high-grade B-lymphoma, transformed follicular lymphoma and mantle cell lymphoma; and in pediatric patients and patients under 25 years of age with acute lymphoblastic leukemia (B-ALL) who do not respond to a defined number of standard therapy lines.
Pemetrexed
Clinical registry of pleural mesothelioma patients who have been treated with pemetrexed (Alimta®).
Tulung
Clinical registry of non-small cell lung cancer (NSCLC) patients who have been treated with bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), pemetrexed (Alimta®), afatinib (Giotrif®) and/or nintedanib (Vargatef®).
